Scarica l'app Stockscreener
9.02
5.55%
-0.53
Precedente Chiudi:
$9.55
Aprire:
$9.61
Volume 24 ore:
3.40M
Relative Volume:
0.44
Capitalizzazione di mercato:
$1.04B
Reddito:
$52.86M
Utile/perdita netta:
$-480.19M
Rapporto P/E:
-1.9233
EPS:
-4.6899
Flusso di cassa netto:
$-421.82M
1 W Prestazione:
-6.14%
1M Prestazione:
-4.95%
6M Prestazione:
+8.02%
1 anno Prestazione:
-33.48%
Intervallo 1D:
$9.02
$9.6799
Intervallo di 1 settimana:
$9.02
$9.95
Portata 52W:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
9.02 | 1.11B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Intellia Therapeutics, Inc. $NTLA Shares Purchased by Armistice Capital LLC - MarketBeat
(NTLA) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Volume Recap: Will Intellia Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Action & Free Weekly Watchlist of Top Performers - moha.gov.vn
Intellia Therapeutics (NASDAQ:NTLA) Nasdaq Index Expands Genetic Research - Kalkine Media
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Why Intellia Therapeutics (NTLA) Is Up 6.9% After Disclosing Serious Liver Safety Events In Lead CRISPR Trials - Sahm
Would You Still Hold Intellia Therapeutics Stock If It Fell Another 30%? - Trefis
Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Should Contact Levi & Korsinsky About Pending Class ActionNTLA - 28/22 News
Schroder Investment Management Group Increases Stock Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Focuses on Pipeline Development Amid Stiff Competition - MSN
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics (NASDAQ: NTLA) issues 12,600 inducement RSUs to three new employees - Stock Titan
Will Intellia Therapeutics Inc. (38I) stock benefit from mergersJuly 2025 Momentum & Weekly Stock Performance Updates - Newser
How analysts revise price targets for Intellia Therapeutics Inc. (38I) stockWeekly Risk Report & Accurate Technical Buy Alerts - Newser
Will Intellia Therapeutics Inc. (38I) stock recover faster than industryMarket Volume Summary & Technical Pattern Alert System - Newser
What dividend safety rating applies to Intellia Therapeutics Inc. (38I) stockMarket Sentiment Report & AI Based Trade Execution Alerts - Newser
Suumaya Corporation Limited Included in Top Momentum ScanFibonacci Extensions & Free Daily Stock Hotspot Analysis - earlytimes.in
Why analysts maintain buy rating on Intellia Therapeutics Inc. (38I) stockJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - Newser
Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory - Finviz
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.1%Should You Buy? - MarketBeat
Does Intellia Therapeutics Inc. (38I) stock trade below intrinsic valueQuarterly Portfolio Review & Fast Exit and Entry Trade Guides - Newser
Is Intellia Therapeutics Inc. stock attractive for growth ETFs2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - Newser
Why Intellia Therapeutics Inc. (38I) stock remains top ratedWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
What is the fair value estimate for Intellia Therapeutics Inc. (38I) stock in 2025Trend Reversal & Accurate Entry/Exit Alerts - Newser
Will Intellia Therapeutics Inc. (38I) stock outperform value peersJuly 2025 Summary & Technical Pattern Based Buy Signals - Newser
Will Intellia Therapeutics Inc. (38I) stock profit from AI boomMarket Activity Summary & Capital Protection Trade Alerts - Newser
Intellia Therapeutics: Critical Safety Updates Are ImminentExpect Volatility (NTLA) - Seeking Alpha
Is Intellia Therapeutics Inc. (38I) stock nearing a technical breakout2025 Price Targets & Weekly High Momentum Picks - Newser
Can Intellia Therapeutics Inc. (38I) stock survive global slowdown - Newser
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble - MSN
Intellia Therapeutics (NASDAQ:NTLA) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Geode Capital Management LLC Boosts Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Can Intellia Therapeutics (NTLA) Rebuild Trust Amid Safety Setbacks and Regulatory Challenges? - Sahm
How (NTLA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade - Yahoo Finance
Intellia Therapeutics, Inc. $NTLA Shares Sold by Orchard Capital Management LLC - MarketBeat
Pullback Watch: Will Intellia Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Weekly Recap & Intraday High Probability Alerts - moha.gov.vn
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? - Nasdaq
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? - sharewise.com
Will Intellia Therapeutics Inc. stock remain a Wall Street favorite2025 Geopolitical Influence & Accurate Intraday Trading Signals - BỘ NỘI VỤ
Operating cash flow per share of Intellia Therapeutics, Inc. – LSX:A2AG6H - TradingView
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of "Hold" from Analysts - MarketBeat
5 Stocks with the Largest Fair Value Estimate Cuts After Q3 Earnings - Morningstar
Intellia Therapeutics Shares: A Crisis Crossroads - Ad-hoc-news.de
Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress - MSN
9 Oversold Biotech Stocks to Invest In - Insider Monkey
NTLA Stockholders Have Opportunity to Lead Intellia Therapeutics - The National Law Review
Intellia Therapeutics, Inc. Sued for Securities Law Violations – - The National Law Review
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? - Finviz
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Intellia Therapeutics Inc Azioni (NTLA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LEONARD JOHN M | President and CEO |
Dec 12 '25 |
Option Exercise |
6.83 |
8,557 |
58,444 |
1,047,485 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Sale |
9.49 |
88,146 |
836,384 |
1,038,928 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):